Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity
Objective: As the obesity pandemic continues to expand, novel molecular targets to reduce obesity-related insulin resistance and Type 2 Diabetes (T2D) continue to be needed. We have recently shown that obesity is associated with reactivated liver Notch signaling, which, in turn, increases hepatic in...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-02-01
|
Series: | Molecular Metabolism |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2212877815002185 |
id |
doaj-5cd97b3acb34442aa129a27401d92fbc |
---|---|
record_format |
Article |
spelling |
doaj-5cd97b3acb34442aa129a27401d92fbc2020-11-24T21:22:20ZengElsevierMolecular Metabolism2212-87782016-02-0152113121Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivityDavid P. Sparling0Junjie Yu1KyeongJin Kim2Changyu Zhu3Sebastian Brachs4Andreas L. Birkenfeld5Utpal B. Pajvani6Departments of Pediatrics, Columbia University, New York, NY 10032, USADepartment of Medicine, Columbia University, New York, NY 10032, USADepartment of Medicine, Columbia University, New York, NY 10032, USADepartment of Medicine, Columbia University, New York, NY 10032, USADepartment of Endocrinology, Diabetes and Nutrition, Center for Cardiovascular Research, Charité – University School of Medicine, Berlin, GermanySection of Metabolic Vascular Medicine, Medical Clinic III and Paul Langerhans Institute Dresden (PLID), a member of the German Center for Diabetes Research (DZD), Technische Universität Dresden, Germany; Section of Diabetes and Nutritional Sciences, Rayne Institute, Denmark Hill Campus, King's College London, UKDepartment of Medicine, Columbia University, New York, NY 10032, USA; Corresponding author. 1150 St. Nicholas Avenue, Room 313A, Columbia University, New York, NY 10032, USA. Tel.: +1 212 851 4886; fax: +1 212 851 4810.Objective: As the obesity pandemic continues to expand, novel molecular targets to reduce obesity-related insulin resistance and Type 2 Diabetes (T2D) continue to be needed. We have recently shown that obesity is associated with reactivated liver Notch signaling, which, in turn, increases hepatic insulin resistance, opening up therapeutic avenues for Notch inhibitors to be repurposed for T2D. Herein, we tested the systemic effects of γ-secretase inhibitors (GSIs), which prevent endogenous Notch activation, and confirmed these effects through creation and characterization of two different adipocyte-specific Notch loss-of-function mouse models through genetic ablation of the Notch transcriptional effector Rbp-Jk (A-Rbpj) and the obligate γ-secretase component Nicastrin (A-Nicastrin). Methods: Glucose homeostasis and both local adipose and systemic insulin sensitivity were examined in GSI-treated, A-Rbpj and A-Nicastrin mice, as well as vehicle-treated or control littermates, with complementary in vitro studies in primary hepatocytes and 3T3-L1 adipocytes. Results: GSI-treatment increases hepatic insulin sensitivity in obese mice but leads to reciprocal lowering of adipose glucose disposal. While A-Rbpj mice show normal body weight, adipose development and mass and unchanged adipose insulin sensitivity as control littermates, A-Nicastrin mice are relatively insulin-resistant, mirroring the GSI effect on adipose insulin action. Conclusions: Notch signaling is dispensable for normal adipocyte function, but adipocyte-specific γ-secretase blockade reduces adipose insulin sensitivity, suggesting that specific Notch inhibitors would be preferable to GSIs for application in T2D. Keywords: Notch, γ-secretase complex, Insulin resistancehttp://www.sciencedirect.com/science/article/pii/S2212877815002185 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
David P. Sparling Junjie Yu KyeongJin Kim Changyu Zhu Sebastian Brachs Andreas L. Birkenfeld Utpal B. Pajvani |
spellingShingle |
David P. Sparling Junjie Yu KyeongJin Kim Changyu Zhu Sebastian Brachs Andreas L. Birkenfeld Utpal B. Pajvani Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity Molecular Metabolism |
author_facet |
David P. Sparling Junjie Yu KyeongJin Kim Changyu Zhu Sebastian Brachs Andreas L. Birkenfeld Utpal B. Pajvani |
author_sort |
David P. Sparling |
title |
Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity |
title_short |
Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity |
title_full |
Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity |
title_fullStr |
Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity |
title_full_unstemmed |
Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity |
title_sort |
adipocyte-specific blockade of gamma-secretase, but not inhibition of notch activity, reduces adipose insulin sensitivity |
publisher |
Elsevier |
series |
Molecular Metabolism |
issn |
2212-8778 |
publishDate |
2016-02-01 |
description |
Objective: As the obesity pandemic continues to expand, novel molecular targets to reduce obesity-related insulin resistance and Type 2 Diabetes (T2D) continue to be needed. We have recently shown that obesity is associated with reactivated liver Notch signaling, which, in turn, increases hepatic insulin resistance, opening up therapeutic avenues for Notch inhibitors to be repurposed for T2D. Herein, we tested the systemic effects of γ-secretase inhibitors (GSIs), which prevent endogenous Notch activation, and confirmed these effects through creation and characterization of two different adipocyte-specific Notch loss-of-function mouse models through genetic ablation of the Notch transcriptional effector Rbp-Jk (A-Rbpj) and the obligate γ-secretase component Nicastrin (A-Nicastrin). Methods: Glucose homeostasis and both local adipose and systemic insulin sensitivity were examined in GSI-treated, A-Rbpj and A-Nicastrin mice, as well as vehicle-treated or control littermates, with complementary in vitro studies in primary hepatocytes and 3T3-L1 adipocytes. Results: GSI-treatment increases hepatic insulin sensitivity in obese mice but leads to reciprocal lowering of adipose glucose disposal. While A-Rbpj mice show normal body weight, adipose development and mass and unchanged adipose insulin sensitivity as control littermates, A-Nicastrin mice are relatively insulin-resistant, mirroring the GSI effect on adipose insulin action. Conclusions: Notch signaling is dispensable for normal adipocyte function, but adipocyte-specific γ-secretase blockade reduces adipose insulin sensitivity, suggesting that specific Notch inhibitors would be preferable to GSIs for application in T2D. Keywords: Notch, γ-secretase complex, Insulin resistance |
url |
http://www.sciencedirect.com/science/article/pii/S2212877815002185 |
work_keys_str_mv |
AT davidpsparling adipocytespecificblockadeofgammasecretasebutnotinhibitionofnotchactivityreducesadiposeinsulinsensitivity AT junjieyu adipocytespecificblockadeofgammasecretasebutnotinhibitionofnotchactivityreducesadiposeinsulinsensitivity AT kyeongjinkim adipocytespecificblockadeofgammasecretasebutnotinhibitionofnotchactivityreducesadiposeinsulinsensitivity AT changyuzhu adipocytespecificblockadeofgammasecretasebutnotinhibitionofnotchactivityreducesadiposeinsulinsensitivity AT sebastianbrachs adipocytespecificblockadeofgammasecretasebutnotinhibitionofnotchactivityreducesadiposeinsulinsensitivity AT andreaslbirkenfeld adipocytespecificblockadeofgammasecretasebutnotinhibitionofnotchactivityreducesadiposeinsulinsensitivity AT utpalbpajvani adipocytespecificblockadeofgammasecretasebutnotinhibitionofnotchactivityreducesadiposeinsulinsensitivity |
_version_ |
1725996302641135616 |